PROLOR Biotech, Inc., a development stage biopharmaceutical company, develops proprietary versions of already-approved therapeutic proteins. The company's technology, Carboxyl Terminal Peptide technology could be attached to an array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity. Its products under development include Human Growth Hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; Erythropoietin for individuals with chronic kidney failure, chemotherapy patients, and HIV/AIDS patients on AZT, as well as for patients who may require a blood transfusion or undergo surgery where blood loss is expected; and Interferon ß that is used to reduce the frequency and severity of relapses afflicting people suffering from multiple sclerosis, as well as Factor VIIa, Factor IX; Anti-Obesity Peptide; and Glucagon-Like Peptide-1. The company was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. PROLOR Biotech, Inc. was founded in 2001 and is based in Nes-Ziona, Israel.